In a Law360 article, life sciences regulatory & compliance partners Kellie Combs and Joshua Oyster and associate Jessica Band analyzed the U.S. Food and Drug Administration long-awaited final rule that amends the agency’s prescription drug advertising regulations addressing the presentation of the so-called “major statement” related to side effects and contraindication in TV and radio ads.
The article summarizes the key aspects of the final rule and important takeaways for marketers of prescription drugs.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.